Background {#Sec1}
==========

Inflammation is a fundamental innate immune response associated with disruption of homeostasis. Increasing evidence suggests a close relationship between systemic inflammation and cancer development and progression \[[@CR1]--[@CR4]\]. Inflammatory leukocytes such as neutrophils, monocytes, macrophages, and eosinophils provide the soluble factors that are thought to mediate the development of inflammation-associated cancer. In recent years, several readily measurable peripheral blood markers such as the neutrophil to lymphocyte ratio (NLR) \[[@CR5]--[@CR10]\], the Glasgow Prognostic score (consisting in a combination of C-reactive protein and albumin level) \[[@CR11]--[@CR13]\], the platelet to lymphocyte ratio \[[@CR14], [@CR15]\] or the Prognostic index (consisting in white blood cell count and C-reactive protein) \[[@CR16]\], were associated with cancer outcomes in large cohort studies. More specifically, the NLR has been recognized as an independent prognostic indicator in various advanced and localized cancer including gastro-intestinal cancers \[[@CR6], [@CR9], [@CR17]--[@CR21]\], urological cancers \[[@CR5], [@CR10], [@CR22], [@CR23]\], lung cancers \[[@CR8], [@CR24]\], head and neck cancers \[[@CR7], [@CR25]\], ovarian cancers \[[@CR8]\], and glioblastomas \[[@CR7]\]. In the case of prostate cancer, studies have reported that NLR was associated with treatment response and survival in patients with metastatic castrate resistant prostate cancer receiving systemic therapy \[[@CR22], [@CR26]\]. However, the prognostic value of markers of systemic inflammation was never previously evaluated in the context of localized prostate cancer.

The following study was designed to explore the influence of readily available markers of systemic inflammation such as leucocyte count and metabolic co-morbidities associated with systemic inflammation on biochemical recurrence-free survival (BRFS) and overall survival (OS) after curative radiotherapy for localized prostate cancer in a large cohort of patients.

Methods {#Sec2}
=======

Patients' characteristics {#Sec3}
-------------------------

Institutional review board (IRB) approval from the Centre Hospitalier de l'Université de Montréal (CHUM) was obtained for this study (Ref 14.144). This being a retrospective study, informed consent was waived by the IRB.

A review of our institutional database of patients with localized prostate cancer treated with definitive external beam radiotherapy or brachytherapy from September 2001 to June 2014 was conducted. Inclusion criteria were: (1) Eastern Cooperative Oncology Group performance status \< 2, (2) histology proven prostate cancer; (2) localized prostate cancer stage T1-3bN0M0 as per the American Joint Committee on Cancer 7th edition; (3) brachytherapy or external beam radiotherapy(EBRT) or a combination of both with curative intent. Prostate cancer risk group was defined as per the National Comprehensive Cancer Network (NCCN) Guidelines classification \[[@CR27]\]. Patients with evidence of radiological or histological lymph node involvement or distant metastasis were excluded. Patients receiving androgen deprivation therapy were included. Initial work-up at diagnosis included: medical history including presence of co-morbidities, physical examination including digital rectal examination, complete blood count and biochemistry, serum prostate specific antigen (PSA), transrectal ultrasound and biopsy. For patients with stage T3-4 disease, PSA ≥10 ng/mL or a Gleason score (GS) ≥7, staging bone scan and pelvic computed tomography (CT) were done at the treating physician's discretion to exclude distant metastasis.

Treatment characteristics {#Sec4}
-------------------------

All patients were treated with curative radiotherapy, with or without androgen deprivation therapy. Low dose rate (LDR) brachytherapy alone with Iodine^125^ permanent seeds to a dose of 144 grays (Gy) was considered for low-risk prostate cancer or intermediate-risk prostate cancer with favorable features. Combined brachytherapy and EBRT (LDR dose of 110 Gy and EBRT dose of 44 Gy in 22 fractions versus HDR dose of 15 Gy in 1 fraction and EBRT dose of 37.5 Gy in 15 fractions) was considered for intermediate or high-risk prostate cancer. When EBRT was given as exclusive therapy, a dose of 70 to 80 Gy was given with or without hormonal therapy.

Follow-up and statistics {#Sec5}
------------------------

Standard follow-up for all patients typically included: physical examination and serum PSA every 3 months for the first 2 years, every 6 months for the following 3 years, and annually thereafter. Biochemical failure was defined as per the Phoenix consensus (nadir + 2 ng/mL) \[[@CR28]\]. Follow-up duration was defined as the time from the date of treatment completion to the date of last follow-up or death. Kaplan-Meier method was used for estimation of OS and BRFS. Univariate and multivariate Cox proportional hazards models analysis were performed to determine predictors of OS and BRFS. Potential baseline predictive factors explored included: age, UCSF Cancer of the prostate risk assessment score (CAPRA) (combining age, PSA, Gleason score, clinical stage and percent positive biopsy cores), body mass index (BMI), metabolic co-morbidities associated with systemic inflammation (cardiovascular disease, diabetes, hypertension, use of statins), as well as leucocyte counts (neutrophils, lymphocytes and neutrophil-to-lymphocyte ratio). Multivariate analysis was carried using stepwise regression method. A stepwise selection of variable based on the Akaike information criterion (AIC) was used for multivariate analysis to determine the best fit model \[[@CR29]\]. Statistical analyses were conducted using SPSS 17 (SPSS, Chicago, IL), SAS 9.4 (SAS Institute, Cary, NC) and R version 2.15.2. All reported p values were considered to be statistically significant at \<0.05 from two-sided tests.

Results {#Sec6}
=======

Patients' characteristics {#Sec7}
-------------------------

In total, 1772 patients were included in the analysis; blood count data was available for 950 patients. Median age was 68 years (range: 44--87). The majority of patients (64 %) presented with stage T1 disease. Low, intermediate and high risk prostate cancer constituted respectively 41 %, 49 % and 10 % of the cohort. In total, 42 % of patients presented a CAPRA score of 0--2, 46 % of 3--5 and 12 % of 6--10. Patients' characteristics including metabolic co-morbidities and leucocyte counts as well as treatment characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Comorbidities included diabetes in 15.1 % of patients, cardiovascular disease in 34.6 % and hypertension in 45.7 %. In addition, 42.6 % of patients used a statin for hypercholesterolemia.Table 1Patients and treatments characteristicsAge (y)  Median (range)6744-87PSA at diagnosis (ng/mL)  Median (range)8.10.2-132AJCC tumor classification (N, %)  T1112664 %  T262732 %  T3804 %Gleason score (N; %)  ≤693053 %  775242 %  ≥8905 %NCCN risk groups (N; %)  Low74842 %  Intermediate85548 %  High16910 %PPC (N, %)  \<34 %88350 %  ≥34 %88350 %CAPRA score\>  0-275943 %  3-581146 %  6-1019411 %BMI  Median (range)28.213.9--52.5Diabetes (N; %)\>  Yes27215 %  No150085 %Statin use (N; %)\>  Yes76243 %  No101057 %CVD (N; %)  Yes62935 %  No114365 %HTN (N; %)  Yes81546 %  No95754 %Lymphocytes (10^3^ cells/μL)  Median (range)1.70.4--16Neutrophils (10^3^ cells/μL)  Median (range)4.50.9--12NLR  Median (range)3.00.1--18.4*Treatment characteristics*Radiotherapy  HDR brachytherapy523 %  LDR brachytherapy90151 %  EBRT81546 %Androgen deprivation\>  Non155187 %  Yes22113 %PSA = prostate-specific antigen; AJCC = American Joint Committee on Cancer; NCCN = National Comprehensive Cancer Network; PPC = percentage of positive cores at prostate biopsies; CAPRA = Cancer of the Prostate Risk Assessment score, BMI = body mass index; CVD = cardiovascular disease; HTN = hypertension. \>HDR = High dose rate; LDR = Low dose rate. Lymphocytes, neutrophils and NLR were available for 950 patients; BMI was available for 544 patients; data was available for entire cohort (1772 patients) for all the other factors.

Biochemical and overall survival outcomes and predictive factors {#Sec8}
----------------------------------------------------------------

Actuarial 5 years OS and BRFS for the entire cohort (1772 patients) was respectively 93 % and 95 %, with a median follow-up of 44 months (range: 1--156) (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). On univariate analysis, neutrophil count (p = 0.04), cardiac history (p = 0.009), age (p = 0.001) and CAPRA (p = 0.0002) were associated with OS (Table [3](#Tab3){ref-type="table"}). Lymphocytes, NLR and comorbidities other than cardiac history were not associated with mortality. On multivariate analysis, neutrophil count (HR = 1.18, 95 % CI: 1.017-1.37, p = 0.028), age (HR = 1.06, 95 % CI: 1.01-1.1, p = 0.008) and CAPRA (HR = 1.16, 95 % CI: 1.03-1.31, p = 0.015) were independent predictors of OS (Table [2](#Tab2){ref-type="table"}).Fig. 1Kaplan Meier OS curve with lower and upper limits of the 95 % confidence intervals showing a 5-year OS of 93 % (95 % CI = 91--95 %) in patients with localized prostate cancer treated with radical radiotherapy or brachytherapyFig. 2Kaplan Meier BRFS curve with lower and upper limits of the 95 % confidence intervals showing a 5-year BFRS of 95 % (95 % CI = 93--96 %) in patients with localized prostate cancer treated with radical radiotherapyTable 2Univariate and multivariate analysis of factors associated with OSUnivariateMultivariateHR (95 % CI)p-valueHR (95 % CI)p-valueAge (n = 1772)1.06 (1.03 1.10)0.0011.05 (1.01--1.10)0.008CAPRA (n = 1772)1.21 (1.09--1.34)0.00021.16 (1.03--1.30)0.015BMI (n = 544)1.00 (0.93--1.06)0.9CVD (n = 1772)1.79 (1.16--2.77)0.009HTN (n = 1772)1.14 (0.74--1.76)0.5Diabetes (n = 1772)1.59 (0.94--2.68)0.08Statin use (n = 1772)0.82 (0.52--1.28)0.40.70 (0.42--1.14)0.15Neutrophils (n = 950)1.16 (1.01--1.34)0.041.18 (1.017--1.37)0.03Lymphocytes (n = 950)1.01 (0.72--1.43)0.9NLR (n = 950)1.10 (0.95--1.27)0.2WBC (n = 950)1.13 (0.99--1.28)0.06n = number of patients with available dataWBC = white blood count (=Neutrophils + Lymphocytes)

On univariate analysis, only CAPRA was associated with BRFS (p = 0.0001). On multivariate analysis, both age (HR = 0.94, 95 % CI 0.91-0.98, p = 0.009) and CAPRA (HR = 1.26, 95 % CI 1.12-1.43, p = 0.0002) were associated with BRFS (Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate analysis of factors associated with BRFSUnivariateMultivariateHR (95 % CI)p-valueHR (95 % CI)p-valueAge (n = 1041)0.98 (0.94--1.01)0.20.94 (0.91--0.98)0.009CAPRA (n = 1041)1.23 (1.11--1.37)0.00011.26 (1.12--1.43)0.0002BMI (n = 372)1.02 (0.97--1.08)0.5CVD (n = 1044)0.73 (0.46--1.16)0.2Diabetes (n = 1044)0.86 (0.44--1.67)0.7Statin use (n = 1044)0.79 (0.50--1.24)0.30.67 (0.39--1.17)0.2Neutrophils (n = 608)1.04 (0.87--1.23)0.7Lymphocytes (n = 609)0.98 (0.64--1.48)0.9NLR (n = 608)1.02 (0.85-1.22)0.9

Discussion {#Sec9}
==========

To our knowledge, this is the first study in the literature reporting an association between neutrophil count and prognosis in localized prostate cancer. In our large study cohort, neutrophil counts were found to be associated with worse OS outcomes. However, such an association was not found for BRFS nor was it found for other markers such as NLR. In addition, in concordance with previous literature \[[@CR30], [@CR31]\], chronological age as well as CAPRA- score as indicator of cancer aggressiveness, were expectedly associated with OS.

The association of neutrophils with survival found in this study is in agreement with the now established association between systemic inflammation and cancer outcomes in many different cancers \[[@CR1], [@CR32]--[@CR34]\], and the increasing evidence supporting the prognostic importance of neutrophil count as a marker of inflammation \[[@CR23], [@CR35], [@CR36]\]. The prognostic significance of neutrophil counts was recently suggested in metastatic prostate cancer. In fact, in a first study by Keizman \[[@CR26]\] where the association between pretreatment NLR and cancer outcome in 156 patients with metastatic castration-resistant prostate cancer treated with ketoconazole was assessed, pretreatment NLR \>3 was found to be associated with worse progression-free survival (PFS) but was not associated with OS. In a second retrospective study including 33 patients with metastatic castrate resistant prostate cancer treated with docetaxel and prednisone \[[@CR37]\], an increased NLR was found to be associated with a decreased PSA response.

Inflammation in cancer and neutrophil count {#Sec10}
-------------------------------------------

How neutrophils affect cancer prognosis remain unclear. Systemic inflammation is believed to be associated with cancer progression through several mechanisms, including: cancer cell development, proliferation and survival, angiogenesis, metastatic potential increase and diminished response to therapy \[[@CR2]\]. In metastatic prostate cancer, molecular signaling triggered by inflammatory mediators was hypothesized to promote cancer cell progression \[[@CR38]\]. Neutrophils are hypothesized to contribute to tumor progression and aggressive biology through the production of cytokines (such as such as tumor necrosis factor, interleukin (IL)-1, and IL-6), chemokines and granule proteins, which are thought to promote tumor proliferation and angiogenesis, and increase its metastatic potential \[[@CR18], [@CR39], [@CR40]\]. On the other hand, the adverse prognosis associated with high NLR could also partly be explained by a lower lymphocyte count which can reflect a decreased anti-tumor immune response, an increased neutrophil response to the tumor and which consequently favors angiogenesis and tumor progression or both \[[@CR41]\].

This being a retrospective study, we were unable to include other known factors of inflammation such as C-reactive protein or albumin levels in this study, because they are not routinely included in laboratory investigations of localized prostate cancer. Neutrophil count and NLR have the advantage of being inexpensive and readily available markers of systemic inflammation. However, although numerous studies support their prognostic role, cut-off values vary significantly among studies, complicating its current use in the clinical setting.

Neutrophil count as prognostic indicator in cancer {#Sec11}
--------------------------------------------------

Several studies have reported an association between increased peripheral neutrophil count and prognosis in numerous cancers, predominantly locally advanced or metastatic. In a study by Teramukai \[[@CR36]\], increased neutrophil count was associated with both decreased OS and PFS in patients with stage IIIB and IV non-small cell lung cancer. Similarly, EORTC 18951 trial showed that both pre-treatment neutrophil and leukocyte counts were independent prognostic factor for OS in patients with metastatic melanoma undergoing immunotherapy \[[@CR35]\]. In addition, a high baseline NLR was found to be a predictor of poor prognosis in many cancers treated with systematic therapy including: malignant mesothelioma \[[@CR42]\], colorectal cancer metastatic to liver \[[@CR17]\], pancreatic cancer \[[@CR6]\], gastric cancer \[[@CR20]\] or advanced esophageal cancer \[[@CR21]\].

One could assume that increased peripheral neutrophils would be associated with worse outcomes in systemic disease only, but numerous studies have reported similar results in localized cancers. In fact, in patients undergoing radical surgery for limited stage cancers, high pre-operative NLR was associated with both worse OS and DSS in colorectal cancer \[[@CR43]\], hepatocellular carcinoma \[[@CR9]\], bladder cancer \[[@CR10]\] renal carcinoma \[[@CR5]\], gastric cancer \[[@CR44]\], and early stage non-small cell lung cancer \[[@CR24]\]. In addition, increased baseline NLR was associated with poorer OS in patients undergoing treatment for glioblastoma multiforme \[[@CR7]\] and nasopharygeal cancer \[[@CR25]\]. In our study, neutrophils were predictive of OS but no such association was found with BRFS. In addition, NLR was associated with neither OS nor BRFS. It is therefore difficult to determine whether systemic inflammation was the cause for cancer progression or simply a marker for systemic inflammation, which could be a cause for an increase in mortality. The number of deaths was too small to stratify according to cause of death in order to determine whether patients with high neutrophils were more likely to die from cardiac problems or prostate cancer. This will be the subject of a later analysis after longer follow-up.

Other markers of systemic inflammation {#Sec12}
--------------------------------------

Many studies have looked at other markers of systemic inflammation. In fact, C-reactive protein alone \[[@CR32]\], the Glasgow prognostic score constituting a combination of C-reactive protein and albumin levels \[[@CR12]\], the platelet to lymphocyte ratio \[[@CR14], [@CR15]\] or the Prognostic index constituted of a combination of C-reactive protein and white cell count \[[@CR11]\], were all shown to be associated with survival in cancer patients. Independent of tumor stage, the Glasgow prognostic score has comprehensively been validated to be prognostic in lung, gastro-intestinal and renal cancers \[[@CR3]\]. In a large cohort of 27 031 cancer patients, Proctor at al. \[[@CR13]\] reported that both the Glasgow score and the Prognostic index had similar prognostic value in cancer, independent of cancer type. Interestingly, their results suggested that rather than the NLR, leucocytes may be best useful addition to the Glasgow score.

Limitations of our study include its retrospective nature with associated selection bias, possible confounding factors and missing data. As leukocyte data was not available for all patients, our study may have been underpowered to detect a statistically significant difference in NLR or lymphocyte counts. Additional known inflammatory markers such as C-reactive protein and albumin level were not routinely available and therefore could not be included in the analysis. In addition, the small number of events and lack of validation cohort precluded the decision to determine a clinically useful neutrophil and age cut-off based on this cohort.

However, we believe that results from this large cohort of patients should be considered at time of treatment decision, especially in older patients. Readily available inflammatory marker such as neutrophil count o better predict survival outcomes and therefore guide optimal treatment decision-making. In fact, a significant proportion of localized prostate cancer is diagnosed in an older population of patients aged ≥ 70 years. For these patients, treatment aggressiveness can vary widely, from watchful waiting to radical local treatment associated with systemic androgen deprivation therapy, depending on their predicted survival outcomes. In addition, a better understanding of the mechanism by which these inflammatory markers contribute to poorer survival may open the door to new targets of systemic therapies.

Conclusion {#Sec13}
==========

Overall mortality in localized prostate cancer depends not only on age and cancer aggressiveness, but also on neutrophil count as a marker of systemic inflammation. Neutrophil counts may prove useful in treatment decision algorithm of these patients. A validation cohort is needed to corroborate these results.
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